Analyst Price Target is $8.00
▲ +243.35% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Alzamend Neuro in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 243.35% upside from the last price of $2.33.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Alzamend Neuro.
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.